ROCKVILLE, Maryland, March 16, 2016 (GLOBE NEWSWIRE) —
MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that it will present five posters at the 2016 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana. Four of the five posters refer to programs that are based on MacroGenics’ Dual-Affinity Re-Targeting (DART®) bispecific technology. The five posters are:
Time: Sunday, April 17, 2016, 1:00 pm – 5:00 pm CDT
Location: Poster Section 27
Poster Board Number: 14
Session Title: Therapeutic Antibodies
Abstract Number: 583
Time: Monday, April 18, 2016, 8:00 am – 12:00 pm CDT
Location: Poster Section 25
Poster Board Number: 20
Session Title: Immune Modulating Agents and Therapeutic Antibodies
Abstract Number: 1489
Time: Monday, April 18, 2016, 8:00 am – 12:00 pm CDT
Location: Poster Section 25
Poster Board Number: 29
Session Title: Immune Modulating Agents and Therapeutic Antibodies
Abstract Number: 1498
Title: Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer
Time: Monday, April 18, 2016, 8:00 am – 12:00 pm CDT
Location: Poster Section 15
Poster Board Number: 10
Session Title: Growth Factor Receptors and Surface Antigens as Therapeutic Targets
Abstract Number: 1201
Time: Tuesday, April 19, 2016, 8:00 am – 12:00 pm CDT
Location: Poster Section 25
Poster Board Number: 14
Session Title: Immune Checkpoints 2
Abstract Number: 3217
About the DART Platform
MacroGenics’ Dual-Affinity Re-Targeting, or DART, platform enables the creation of potential medicines comprised of a single antibody-like molecule designed to simultaneously bind to two target antigens. The Company has created over 100 DART molecules with potential therapeutic applications spanning treatment of cancer, autoimmune disorders and infectious diseases. DART molecules can be tailored for either short or prolonged pharmacokinetics and have demonstrated good stability and attractive manufacturability. The versatility of the DART platform allows for the exploitation of a variety of intended mechanisms of action. Today, six DART product candidates, including those licensed to collaboration partners, are in or near clinical studies, with several additional product candidates in pre-clinical development.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company’s website at www.macrogenics.com. DART, MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of the Company’s therapeutic candidates, milestone or opt-in payments from the Company’s collaborators, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company’s product candidates and other risk factors described in the Company’s filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
CONTACT: CONTACT: Jim Karrels, Senior Vice President, CFO MacroGenics, Inc. 1-301-251-5172, info@macrogenics.com Karen Sharma, Senior Vice President MacDougall Biomedical Communications 1-781-235-3060, ksharma@macbiocom.com
